| 2020 | | A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis | 서창희 |
| 2023 | | A link between CD8+CD27-CD28- T cells expressing chemerin chemokine-like receptor 1 and rheumatoid arthritis | 김경민, 김현아, 박선, 정주양 |
| 2017 | | A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis | 서창희 |
| 2020 | | A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis | 서창희 |
| 2023 | | Association between CCR2 and CCL2 expression and NET stimulation in adult-onset Still’s disease | 김지원, 김현아, 서창희, 정주양, 한재호 |
| 2022 | | Association between nuclear factor of activated T cells C2 polymorphisms and treatment response in rheumatoid arthritis patients receiving tumor necrosis factor-alpha inhibitors | 김현아, 정주양 |
| 2023 | | Association between SYVN1 and SEL1 genetic polymorphisms and remission in rheumatoid arthritis patients treated with TNF-α inhibitors: a machine learning approach | 김현아, 정주양 |
| 2021 | | Association of TLR 9 gene polymorphisms with remission in patients with rheumatoid arthritis receiving TNF-α inhibitors and development of machine learning models | 정주양 |
| 2016 | | Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis | 서창희 |
| 2021 | | Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature | 김영배, 김지원, 김현아, 서창희, 정주양 |
| 2023 | | Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview | 서창희 |
| 2017 | | Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab | 김현아, 서창희 |
| 2024 | | Clinical characteristics and prognostic factors of non-tuberculous mycobacterial disease in patients with rheumatoid arthritis | 김지원, 김현아, 서창희, 정주양 |
| 2023 | | Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | 김현아 |
| 2017 | | Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis | 김현아, 서창희 |
| 2018 | | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial | 서창희 |
| 2016 | | Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA | 김현아, 서창희, 정주양 |
| 2019 | | Differences in Expression of Human Leukocyte Antigen Class II Subtypes and T Cell Subsets in Behcet's Disease with Arthritis | 김현아, 서창희, 손성향, 정주양 |
| 2021 | | Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: Real-world data from the KOBIO registry | 김현아 |
| 2022 | | Effects of RETN polymorphisms on treatment response in rheumatoid arthritis patients receiving TNF-α inhibitors and utilization of machine-learning algorithms | 김현아, 정주양 |
| 2023 | | Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry | 김지원, 김현아, 서창희, 정주양 |
| 2017 | | Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis | 서창희 |
| 2019 | | Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial | 서창희 |
| 2017 | | Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial | 서창희 |
| 2019 | | Evaluation of factors affecting the levels of physical activity in patients with rheumatoid arthritis: a cross-sectional study | 부선주, 서창희, 정주양 |
| 2022 | | Factors affecting quality of life in patients with rheumatoid arthritis in South Korea: a cross-sectional study | 김지원, 부선주, 서창희 |
| 2018 | | Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months | 서창희 |
| 2021 | | Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry | 김현아 |
| 2015 | | High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. | 서창희 |
| 2017 | | Highly Expression of CD11b and CD32 on Peripheral Blood Mononuclear Cells from Patients with Adult-Onset Still's Disease | 김현아, 서창희, 손성향, 정주양 |
| 2020 | | Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis | 서창희 |
| 2016 | | Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus | 서창희 |
| 2017 | | Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis | 부선주, 서창희 |
| 2012 | | Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea | 김현아, 서창희 |
| 2019 | | Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial | 서창희 |
| 2019 | | Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study | 서창희 |
| 2019 | | Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica | 김현아, 서창희, 정주양 |
| 2016 | | Perceived and actual risk of cardiovascular disease in patients with rheumatoid arthritis in Korea: A cross-sectional study | 부선주, 서창희, 정주양 |
| 2014 | | Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls. | 김현아, 서창희 |
| 2020 | | Preclinical rheumatoid arthritis and rheumatoid arthritis prevention | 김현아 |
| 2023 | | Predicting physical activity and sarcopenia-related health outcomes in women with rheumatoid arthritis: A test of the self-determination theory | 김춘자, 정주양 |
| 2021 | | Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review | 김지원, 서창희, 정주양 |
| 2023 | | Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study | 김지원, 김현아, 서창희, 정주양 |
| 2020 | | Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry | 김현아 |
| 2015 | | Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines. | 서창희 |
| 2005 | | Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis. | 남동호, 박해심, 서창희, 조재현 |
| 2019 | | Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis | 김지원, 김현아, 서창희, 정주양 |
| 2016 | | Salivary cortisol levels, but not salivary alpha-amylase levels, are elevated in patients with rheumatoid arthritis irrespective of depression | 김현아, 박샛별, 서창희 |
| 2012 | | Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease | 김현아, 서창희, 전자영 |
| 2020 | | Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity | 서창희 |
| 2017 | | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry | 김현아 |
| 2016 | | TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still's Disease and Their Association with Disease Activity and Clinical Manifestations | 김유선, 김현아, 서창희, 임현이, 정주양, 한재호 |
| 2017 | | Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis | 김현아, 서창희, 정윤석, 정주양, 최용준 |
| 2020 | | Trabecular Bone Score Is a Useful Parameter for the Prediction of Vertebral Fractures in Patients With Polymyalgia Rheumatica | 김현아, 서창희, 정윤석, 정주양, 최용준 |
| 2018 | | Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea | 서창희 |
| 2022 | | Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis | 서창희 |
| 2023 | | Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry | 김지원, 김현아, 서창희, 정주양 |
